Ascentage Pharma Group International (AAPG) Competitors $32.02 +2.27 (+7.63%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock AAPG vs. BPMC, ROIV, RVMD, BBIO, ELAN, VRNA, LEGN, TGTX, GRFS, and TLXShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Its Competitors Blueprint Medicines Roivant Sciences Revolution Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Legend Biotech TG Therapeutics Grifols Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines (NASDAQ:BPMC) and Ascentage Pharma Group International (NASDAQ:AAPG) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends. Does the MarketBeat Community favor BPMC or AAPG? Blueprint Medicines received 553 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 66.99% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes55466.99% Underperform Votes27333.01% Ascentage Pharma Group InternationalOutperform Votes1100.00% Underperform VotesNo Votes Does the media refer more to BPMC or AAPG? In the previous week, Blueprint Medicines had 7 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 11 mentions for Blueprint Medicines and 4 mentions for Ascentage Pharma Group International. Blueprint Medicines' average media sentiment score of 0.75 beat Ascentage Pharma Group International's score of 0.73 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BPMC or AAPG? Blueprint Medicines presently has a consensus target price of $129.35, suggesting a potential upside of 0.89%. Given Blueprint Medicines' higher possible upside, research analysts clearly believe Blueprint Medicines is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.32Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BPMC or AAPG more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Ascentage Pharma Group International's return on equity of 0.00% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-13.19% -77.49% -20.84% Ascentage Pharma Group International N/A N/A N/A Which has preferable valuation and earnings, BPMC or AAPG? Ascentage Pharma Group International has higher revenue and earnings than Blueprint Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M14.73-$67.09M-$2.47-51.91Ascentage Pharma Group International$980.65M2.84N/AN/AN/A SummaryBlueprint Medicines beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79B$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1719.96Price / Sales2.84262.53410.96157.63Price / CashN/A65.8538.2534.64Price / BookN/A6.597.064.69Net IncomeN/A$143.75M$3.23B$248.14M7 Day Performance12.83%0.82%0.77%0.95%1 Month Performance33.19%12.09%9.67%5.74%1 Year PerformanceN/A4.46%32.02%14.73% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$32.02+7.6%N/AN/A$2.79B$980.65M0.00600Gap UpBPMCBlueprint Medicines1.1806 of 5 stars$127.850.0%$129.35+1.2%+20.8%$8.26B$562.12M-118.38640High Trading VolumeROIVRoivant Sciences2.4073 of 5 stars$11.23+0.3%$17.50+55.8%+5.9%$8.01B$29.05M-74.86860RVMDRevolution Medicines4.4546 of 5 stars$41.09+2.2%$67.08+63.3%+2.8%$7.65B$742K-11.45250Positive NewsBBIOBridgeBio Pharma4.5684 of 5 stars$38.62+0.7%$57.09+47.8%+38.2%$7.33B$127.42M-13.55400Trending NewsInsider TradeAnalyst RevisionELANElanco Animal Health1.0644 of 5 stars$13.95+3.8%$15.17+8.8%-20.6%$6.93B$4.43B34.869,800VRNAVerona Pharma2.1857 of 5 stars$84.34-1.4%$82.13-2.6%+527.1%$6.84B$118.54M-43.9330Positive NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.0777 of 5 stars$35.00+11.2%$76.20+117.7%-17.1%$6.43B$728.30M-36.841,070Short Interest ↑Analyst RevisionHigh Trading VolumeTGTXTG Therapeutics2.9523 of 5 stars$40.06+1.9%$40.80+1.8%+122.3%$6.36B$386.39M-400.56290Analyst RevisionGRFSGrifols3.8381 of 5 stars$8.82+1.1%N/A+27.7%$6.00B$7.21B7.5426,300Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.77-3.4%$22.00+31.2%N/A$5.67B$783.21M0.00N/ANews CoverageAnalyst Forecast Related Companies and Tools Related Companies BPMC Alternatives ROIV Alternatives RVMD Alternatives BBIO Alternatives ELAN Alternatives VRNA Alternatives LEGN Alternatives TGTX Alternatives GRFS Alternatives TLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AAPG Stock Free AAPG Stock Alerts